Allergy Therapeutics (Canada) Ltd. is voluntarily withdrawing these products from the Canadian market. While these products have been sold for more than 10 years regulatory data have never been submitted for review. The necessary data is being collected, but until such time as Health Canada reviews this data and grants appropriate regulatory approval, these products will no longer be available. Allergy Therapeutics (Canada) has never received any adverse reactions respecting Pollinex T or Pollinex G, however, physicians may wish to evaluate the risk benefit to patients prior to continuing any therapy which has already been initiated.

(Note: This does not apply to Pollinex R for ragweed immunotherapy)

Hevea latex from the Maylasian Rubber Tree, with 9 of its 250 Proteins having been demonstrated as allergenic, has been responsible for a number of allergic reactions especially among health care workers and individuals who have had multiple surgeries. Yulex Corporation of southern California now has a process to produce a hypoallergenic latex from the Guayule plant, which is indigenous to the southern U.S. and northern Mexico, and has 10-30 times fewer proteins. Latex sensitive people tested so far have not cross reacted. These gloves should arrive on the market next year.